These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36002078)

  • 1. Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities.
    Shao S; Zhang X; Xu Q; Pan R; Chen Y
    Pharmacol Ther; 2022 Nov; 239():108270. PubMed ID: 36002078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
    Sloan LA
    J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists: Exploring the mechanisms from glycemic control to treatment of multisystemic diseases.
    Kong MW; Yu Y; Wan Y; Gao Y; Zhang CX
    World J Gastroenterol; 2024 Sep; 30(36):4036-4043. PubMed ID: 39351253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
    Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK
    Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches.
    Morissette A; Mulvihill EE
    J Pharm Pharm Sci; 2024; 27():13065. PubMed ID: 38903652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD.
    Jiang H; Zang L
    Curr Pharm Des; 2024; 30(2):100-114. PubMed ID: 38532322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
    Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
    Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Consensus recommendations on utilizing glucagon-like peptide-1(GLP-1) receptor agonists in the treatment of type 2 diabetes mellitus].
    ;
    Zhonghua Nei Ke Za Zhi; 2020 Nov; 59(11):836-846. PubMed ID: 33120487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
    Tzotzas T; Karras SN; Katsiki N
    Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.
    Dash S
    Diabetes Obes Metab; 2024 Sep; 26 Suppl 4():3-15. PubMed ID: 39157881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH; Chang CH; Lin JW; Yang WS; Wu LC; Toh S
    Diabetes Obes Metab; 2022 Aug; 24(8):1623-1637. PubMed ID: 35491533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.